Table 2.

Risk of CKD and aRRT

Smoking statusa	Individuals with CKD during follow-up	IR per 10,000 PYFU (95% CI)	IRR (95% CI)
			Unadjusted	Adjusted
Risk of CKDb
Never	47	83.2 (62.5–110.8)	Ref	Ref
Previous	43	132.7 (98.4–178.9)	1.6 (1.1–2.4)	1.1 (0.7–1.7)
Current	90	97.4 (79.2–119.7)	1.2 (0.8–1.6)	1.3 (0.9–1.8)
Risk of aRRT
Never	20	20.6 (13.3–31.9)	Ref	Ref
Previous	11	22.0 (12.2–39.7)	1.1 (0.5–2.2)	0.8 (0.4–1.7)
Current	31	21.4 (15.0–30.4)	1.0 (0.6–1.8)	0.9 (0.5–1.7)

Notes:

^aAt study inclusion;

^bdefinition of CKD: two consecutive CG-CrCls of ≤60 mL/min ≥3 months apart. For CKD: adjusted for age, gender, HAART exposure, tenofovir exposure, race, route of infection, comorbidities (diabetes, hypertension, and AIDS), included as time-updated variables, CD4 cell count, and CG-CrCl at study inclusion. For aRRT: adjusted for age, gender, HAART exposure, tenofovir exposure, race, route of infection, comorbidities (diabetes, hypertension, and AIDS), included as time-updated variables and CD4 cell count.

Abbreviations: CKD, chronic kidney disease; aRRT, any renal replacement therapy; IR, incidence rate; PYFU, person years of follow-up; CI, confidence interval; IRR, incidence rate ratio; CG-CrCl, estimated creatinine clearance calculated with the Cockcroft–Gault equation; HAART, highly active antiretroviral treatment; AIDS, acquired immunodeficiency syndrome; Ref, reference.